DRMA

Company Overview — What Does Dermata Therapeutics, Inc. Do?

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics, Inc. (DRMA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gerry Proehl and employs approximately 8 people. With a market capitalization of $5M, DRMA is one of the notable companies in the Healthcare sector.

Dermata Therapeutics, Inc. (DRMA) Stock Rating — Reduce (April 2026)

As of April 2026, Dermata Therapeutics, Inc. receives a Reduce rating with a composite score of 23.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DRMA ranks #3,844 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Dermata Therapeutics, Inc. ranks #650 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DRMA Stock Price and 52-Week Range

Dermata Therapeutics, Inc. (DRMA) currently trades at $1.22. The stock gained $0.01 (1.0%) in the most recent trading session. The 52-week high for DRMA is $7.14, which means the stock is currently trading -82.9% from its annual peak. The 52-week low is $0.57, putting the stock 112.9% above its annual trough. Recent trading volume was 75K shares, suggesting relatively thin trading activity.

Is DRMA Overvalued or Undervalued? — Valuation Analysis

Dermata Therapeutics, Inc. (DRMA) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.87x, versus the sector average of 2.75x.

At current multiples, Dermata Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Dermata Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Dermata Therapeutics, Inc. (DRMA) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -142.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -112.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DRMA Debt, Balance Sheet, and Financial Health

Dermata Therapeutics, Inc. has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.79x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

DRMA has a beta of -3.52, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Dermata Therapeutics, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Dermata Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Dermata Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-8.16. Net income for the quarter was $-9M. Operating income came in at $-9M.

In FY 2025, Dermata Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-8.16. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q3 2025, Dermata Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.65. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Dermata Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.66. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, Dermata Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing DRMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DRMA Dividend Yield and Income Analysis

Dermata Therapeutics, Inc. (DRMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DRMA Momentum and Technical Analysis Profile

Dermata Therapeutics, Inc. (DRMA) has a momentum factor score of 20/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

DRMA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Dermata Therapeutics, Inc. (DRMA) ranks #650 out of 838 stocks based on the Blank Capital composite score. This places DRMA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DRMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DRMA vs S&P 500 (SPY) comparison to assess how Dermata Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

DRMA Next Earnings Date

No upcoming earnings date has been announced for Dermata Therapeutics, Inc. (DRMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DRMA? — Investment Thesis Summary

The quantitative profile for Dermata Therapeutics, Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 20/100, a headwind for near-term performance. High volatility (stability score 30/100) increases portfolio risk.

In summary, Dermata Therapeutics, Inc. (DRMA) earns a Reduce rating with a composite score of 23.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DRMA stock.

Related Resources for DRMA Investors

Explore more research and tools: DRMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DRMA head-to-head with peers: DRMA vs AZN, DRMA vs SLGL, DRMA vs VMD.